Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.

Details

Serval ID
serval:BIB_B02180461EEC
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.
Journal
Cancers
Author(s)
Teixeira Farinha H., Digklia A., Schizas D., Demartines N., Schäfer M., Mantziari S.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
22/01/2022
Peer-reviewed
Oui
Volume
14
Number
3
Pages
554
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
The management of esophageal cancer (EC) has experienced manifold changes during the last decades. Centralization of EC treatment has been introduced in many countries, subsequently allowing the development of specialized high-volume centers. Minimal invasive surgery has replaced open surgery in many centers, whereas more potent systemic treatments have been introduced in clinical practice. Newer chemotherapy regimens increase long-term survival. Nevertheless, the overall survival of EC patients remains dismal for advanced tumor stages. In this direction, a wide range of targeted biologic agents (immunotherapy) is currently under assessment. Anti- Human Epidermal Growth Factor Receptor-2 (HER-2) monoclonal antibodies are used in HER2 (+) tumors, predominantly well-differentiated adenocarcinomas, and are currently assessed in the neoadjuvant setting (TRAP, INNOVATION trials). Immune checkpoint inhibitors Nivolumab (ATTRACTION-03) and pembrolizumab (KEYNOTE-181), have demonstrated a survival benefit compared with conventional chemotherapy in heavily pre-treated progressive disease. More recently, CheckMate-577 showed very promising results for nivolumab in a curative adjuvant setting, improving disease-free survival mainly for esophageal squamous cell carcinoma. Several ongoing trials are investigating novel targeted agents in the preoperative setting of locally advanced EC. In addition, other immunomodulatory approaches such as peptide vaccines and tumor infiltrating lymphocytes (TILs) are currently under development and should be increasingly integrated into clinical practice.
Keywords
esophageal adenocarcinoma, immunotherapy, oesophageal cancer, squamous cell cancer, tumor microenvironment
Pubmed
Open Access
Yes
Create date
19/02/2022 12:09
Last modification date
23/02/2022 7:36
Usage data